Anemia News and Research

RSS

Anemia is a decrease in normal number of red blood cells (RBCs) or less than the normal quantity of hemoglobin in the blood. However, it can include decreased oxygen-binding ability of each hemoglobin molecule due to deformity or lack in numerical development as in some other types of hemoglobin deficiency. The three main classes of anemia include excessive blood loss (acutely such as a hemorrhage or chronically through low-volume loss), excessive blood cell destruction (hemolysis) or deficient red blood cell production (ineffective hematopoiesis). Anemia is the most common disorder of the blood. There are several kinds of anemia, produced by a variety of underlying causes. Anemia can be classified in a variety of ways, based on the morphology of RBCs, underlying etiologic mechanisms, and discernible clinical spectra, to mention a few.

Ligand Pharmaceuticals: GSK granted marketing authorization from EC for Revolade

Ligand Pharmaceuticals Incorporated today announced that GlaxoSmithKline was granted marketing authorization from the European Commission for Revolade® (eltrombopag) for the oral treatment of thrombocytopenia (reduced platelet count) in adults with the blood disorder chronic immune (idiopathic) thrombocytopenic purpura (ITP).

15 Mar 2010

Eisai's Dacogen five-day dosing regimen for treatment of MDS receives FDA approval

Eisai Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved a five-day dosing regimen for Dacogen® (decitabine) for Injection to treat patients with myelodysplastic syndromes (MDS), a group of bone marrow diseases that alter the production of functional blood cells.

12 Mar 2010

Platelet dosage can be lowered in transfusions for cancer and bone-marrow transplant patients

Physicians may be able to safely lower the platelet dosage in transfusions for cancer and bone-marrow transplant patients without risking increased bleeding, according to new research involving UT Southwestern Medical Center and 28 other medical institutions.

11 Mar 2010

Affymax initiates Phase 3 clinical testing of Hematide in Japan, receives $5M milestone payment

Affymax, Inc. today announced that it has received a $5 million development milestone payment from Takeda Pharmaceutical Company as part of the companies’ exclusive global agreement to develop and commercialize Hematide™, Affymax’s investigational drug for the treatment of anemia in chronic renal failure patients. The milestone was achieved with the initiation of Phase 3 clinical testing of Hematide to treat anemia in chronic renal failure patients in Japan.

10 Mar 2010

Children's Hospital Boston develops new web site, releases video message on current state of stem cell research

Exactly one year to the day after President Obama's historic decision to reverse an eight-year restriction on federally funded embryonic stem cell research, the Children's Hospital Boston Stem Cell Program today announced the development of a unique, comprehensive web site and released a candid video message from its top researchers on the current state of stem cell research to introduce the new site: stemcell.childrenshospital.org.

10 Mar 2010

Combating DVT and PE: Critical recommendations

Three critical recommendations from a national workshop have been released to address deep-vein thrombosis (DVT) and pulmonary embolism (PE), a growing public health problem estimated to affect nearly 1 million Americans each year.

10 Mar 2010

Alison Walker selected to receive ASH-AMFDP Award

Alison Walker, MD, has been selected to receive the ASH-AMFDP Award, and will begin her research in acute myeloid leukemia in July of this year. The award, designed to help increase the number of underrepresented minority scholars in the field of hematology, is the result of a partnership between the American Society of Hematology and the Harold Amos Medical Faculty Development Program of the Robert Wood Johnson Foundation.

10 Mar 2010

IBS patients are at no greater risk of having polyps, colon cancer than healthy people undergoing colonoscopies

Patients with irritable bowel syndrome are at no greater risk of having polyps, colon cancer or inflammatory bowel diseases than healthy people undergoing colonoscopies, according to new research published in the American Journal of Gastroenterology.

10 Mar 2010

False positives in screening tests

In many jurisdictions, tests for human immunodeficiency virus (HIV) are required screening for pregnant women. Some even suggest screening the entire population for HIV. The rationale is to administer powerful antiretroviral drugs to healthy individuals to "prevent transmission."

10 Mar 2010

Entelos, RegeneMed release iToxFX to screen novel compounds for potential toxicity issues

Entelos, Inc., a simulation and modeling company focused on human health, and RegeneMed, Inc., a tissue-based drug discovery and regenerative medicine company, announced today the release of iToxFX™.

8 Mar 2010

'Anti-gluten pill' needed

In the early 1980s, about one per cent of adults in Finland had gluten intolerance, but the figure has since gone up to two per cent by the 2000s.

5 Mar 2010

Recipients for 2010 Scholar Awards announced

The American Society of Hematology announces the 2010 recipients of its Scholar Awards. The program is designed to support hematologists who have chosen a career in research by providing partial salary or other support during that critical period required for completion of training and achievement of status as an independent investigator.

5 Mar 2010

Greater use of ESAs and iron at lower hematocrit levels decrease risk of death for hemodialysis patients

Greater use of erythropoiesis-stimulating agents (ESAs) and more frequent use of iron at lower hematocrit levels (the proportion of the blood that consists of red blood cells) was associated with a decreased risk of death for hemodialysis patients, according to a study in the March 3 issue of JAMA.

3 Mar 2010

Aggressive treatment of anemia with ESAs may lower risk of death for dialysis patients: Study

Aggressive treatment of anemia with intravenous iron and drugs known as erythropoiesis-stimulating agents (ESAs) may lower the risk of death for dialysis patients with severe anemia - but also may increase the risk of death among patients with milder anemia, a new study led by a University of North Carolina at Chapel Hill epidemiologist suggests.

3 Mar 2010

Critical follow-up evaluations provide opportunity to help physicians best evaluate their HF patients

Heart failure is by far the most prevalent chronic cardiac condition. Around 30 million people in Europe have heart failure and its incidence is still increasing: more cases are being identified, more people are living to an old age, and more are surviving a heart attack but with damage to the heart muscle.

2 Mar 2010

Colonoscopy screening recommended for people with family history of colon cancer

A family history of colon cancer, also known as colorectal cancer or CRC, puts people at higher than average risk for developing the disease.

2 Mar 2010

Canyon Pharmaceuticals announces the availability of Iprivask inhibitor for prevention of DVT

Canyon PharmaceuticalsTM (www.canyonpharma.com) today announced the availability of Iprivask (desirudin for injection), the first direct thrombin inhibitor (DTI) approved in the United States by the Food and Drug Administration for the prevention of deep vein thrombosis (DVT), which may lead to pulmonary embolism in patients undergoing elective hip replacement surgery.

2 Mar 2010

AMAG Pharmaceuticals reports fourth-quarter 2009 net product revenues of $12.8M attributable to Feraheme

AMAG Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease, today reported unaudited consolidated financial results for the fourth quarter and year ended December 31, 2009.

1 Mar 2010

Determining personal risk for genetic disorders essential

Genetic diseases affect an estimated 12 million Americans, yet according to a survey of 1,000 people conducted by the Genetic Disease Foundation (GDF), while two-thirds of those surveyed were willing to and saw the benefits of undergoing genetic testing, close to 80 percent had never talked to their physician about genetic screening – an inconsistency that can have serious implications on a person's overall health and the health of their immediate family members.

1 Mar 2010

Precise immune disturbances leading to Coeliac disease: More insight

New research has identified four aspects of immune system disturbance which lead to the development of coeliac disease. Nearly 40 different inherited risk factors which predispose to the disease have now been identified. These latest findings could speed the way towards improved diagnostics and treatments for the autoimmune complaint that affects 1 in 100 of the population, and lead to insights into related conditions such as type 1 diabetes.

28 Feb 2010

Anemia News and Research

Further Reading

Ligand Pharmaceuticals: GSK granted marketing authorization from EC for Revolade

Eisai's Dacogen five-day dosing regimen for treatment of MDS receives FDA approval

Platelet dosage can be lowered in transfusions for cancer and bone-marrow transplant patients

Affymax initiates Phase 3 clinical testing of Hematide in Japan, receives $5M milestone payment

Children's Hospital Boston develops new web site, releases video message on current state of stem cell research

Combating DVT and PE: Critical recommendations

Alison Walker selected to receive ASH-AMFDP Award

IBS patients are at no greater risk of having polyps, colon cancer than healthy people undergoing colonoscopies

False positives in screening tests

Entelos, RegeneMed release iToxFX to screen novel compounds for potential toxicity issues

'Anti-gluten pill' needed

Recipients for 2010 Scholar Awards announced

Greater use of ESAs and iron at lower hematocrit levels decrease risk of death for hemodialysis patients

Aggressive treatment of anemia with ESAs may lower risk of death for dialysis patients: Study

Critical follow-up evaluations provide opportunity to help physicians best evaluate their HF patients

Colonoscopy screening recommended for people with family history of colon cancer

Canyon Pharmaceuticals announces the availability of Iprivask inhibitor for prevention of DVT

AMAG Pharmaceuticals reports fourth-quarter 2009 net product revenues of $12.8M attributable to Feraheme

Determining personal risk for genetic disorders essential

Precise immune disturbances leading to Coeliac disease: More insight

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News